According to a new report, published by KBV research, The Global Gabapentin Market size is expected to reach $2.6 billion by 2028, rising at a market growth of 4.5% CAGR during the forecast period.
The Neuropathic Pain segment is showcasing a CAGR of 5.5% during (2022 - 2028). Because illness is becoming more common and therapies are being used more frequently, the neuropathic pain segment will grow throughout the forecast period. Many people worldwide experience neuropathic pain. In addition, due to efforts being made to lessen opioid dependency, gabapentin consumption is increasing to treat episodes of neuropathic pain.
The Capsule segment is leading the Global Gabapentin Market by Dosage Form in 2021 thereby, achieving a market value of $1.5 billion by 2028. The segment's dominance is explained by the speedier mechanism of action as well as greater acceptance of the capsule dosage form. Additionally, the market expansion is being fueled by the high rate of prescriptions for capsules as well as the accessibility of well-known brands in the industry like Neurontin and Gralise. These capsules are often provided in quantities of 500 mg, 300 mg, and 100 mg.
The Retail Pharmacy segment has shown the growth rate of 5% during (2022 - 2028). The segment is growing because of the close proximity, expertise, and availability of a pharmacist. As a result, many people prefer the services of these pharmacies more often. Additionally, the retail pharmacy sector is expanding as pharmacies form groupings and chains. Moreover, the higher penetration rate of these pharmacies along with a substantial inventory are aiding in the segment’s growth.
The North America market dominated the Global Gabapentin Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $997.7 million by 2028. The Europe market is exhibiting a CAGR of 4% during (2022 - 2028). Additionally, The Asia Pacific market would display a CAGR of 5.2% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/gabapentin-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Limited, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Teva Pharmaceuticals Industries Ltd., Aurobindo Pharma Limited, Amneal Pharmaceuticals, Inc., Cipla Limited, and Apotex, Inc.
By Application
By Dosage Form
By Distribution Channel
By Geography
Companies Profiled
Unique Offerings 
